title: Clinical management of agitation in the elderly with tiapride.
abstract: Agitated behaviors such as uncooperativeness with necessary care, motor hyperactivity, and verbal or physical aggression are some of the most commonly reported complications in dementia and organic disorders in elderly subjects. These symptoms present greater clinical challenges and management issues than the cognitive deficits. Antipsychotics are the most commonly used psychotropic agents for treating these types of symptoms. The aims of this article are to review clinical studies with tiapride, a substituted benzamide, and more specifically to present recent data coming from two double-blind, randomized studies in elderly subjects. The first study versus melperone was conducted in Germany, with over 176 hospitalized demented patients, and indicated that tiapride was as effective and safe as melperone. More recently, a multicentre, international, double-blind, three-parallel group study compared a 21-day treatment of tiapride to haloperidol and placebo and included 306 demented elderly patients with agitation and aggressiveness. The results showed that tiapride and haloperidol were significantly effective in the treatment of agitation and aggressiveness compared to placebo. The tiapride safety profile was found to be better than haloperidol for clinical acceptability, particularly for significantly fewer extrapyramidal symptoms in the tiapride group.
authors.affiliation: Memory Centre, Psychiatric Clinic, CHU, Hôpital Pasteur, 30 avenue de la Voie Romaine, 06002 Nice cedex 1, France. PHILIPPE.robert15@wanadoo.fr
authors.forename: P H
authors.initials: PH
authors.lastname: Robert
authors.forename: H
authors.initials: H
authors.lastname: Allain
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000523:psychology*; D018726:Anti-Dyskinesia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006801:Humans; D011595:Psychomotor Agitation / Q000188:drug therapy* / Q000209:etiology*; D012720:Severity of Illness Index; D013976:Tiapamil Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D018726:Anti-Dyskinesia Agents; D013976:Tiapamil Hydrochloride